Nebido - future market leader?

[Guest guest]

Was reading a book on hypogonadism - Jockenhovel, F., and Schubert, M.

(2007). `Male hypogonadism'. Uni-Med Science.- which is pretty recent

and it stated Nebido will be the standard treatment for hypogonadism

because it has favourable effects with regards to libido, bones and

muscle mass, low incidence of side effects and is more stable therefore

avoiding the peaks and troughs normally seen with shorter acting

injectables.

Also more acceptable to users because only needs to be injected 4/5

times a year as opposed to 26-52 times - quite a difference. Probably

its biggest selling point!

However since its market launch in 2004 in Europe it does not seem to

be the market leader and I do not hear of many people using it. Anyone

know why this is?

Anyone got good/bad experiences on it they can share?

I know the FDA is currently working with Indevus Pharmaceuticals

(license for Nebido bought from Bayer Schering Pharma) and has been

unhappy with some respiratory side effects in few users (at least 1/100

people) and therefore wants the company to suggest and implement ways

to reduce these effects before an FDA license will be granted for US

market release.

Will be interesting to see how this one develops.